Literature DB >> 34633539

Influence of the treatment with the antineoplastic agents 5-fluorouracil and cisplatin on the severity of experimental periodontitis in rats.

Vivian Cristina Noronha Novaes1, Edilson Ervolino2, Giovani Lopes Fernandes1, Clara Possarle Cunha1, Leticia Helena Theodoro1, Valdir Gouveia Garcia1, Juliano Milanezi de Almeida3.   

Abstract

PURPOSE: The determination on how antineoplastic agents interfere on the progression of periodontitis is critical for improvement and even development of novel therapeutic approaches for periodontal management. This study evaluated the influence of chemotherapy with 5-fluorouracil (5-FU) or cisplatin (CIS) on healthy periodontal tissues and on the progression of experimental periodontitis (EP).
METHODS: One hundred forty-four male rats were divided into six groups (n = 24). Each group was treated with physiological saline solution (PSS) 0.9%, 5-FU, or CIS. Experimental periodontitis (EP) was induced by ligature placement. Animals were euthanized at 7, 15, and 30 days after treatment. Data were statistically analyzed (p ≤ 0.05).
RESULTS: The groups with EP and treated with 5-FU or CIS showed lower percentage of bone volume in the furcation region and higher percentage of alveolar bone loss, higher number of TRAP-positive cells, and lower number of PCNA-positive cells when compared group with EP and treated with PSS (p ≤ 0.05). Groups with EP and treated with 5-FU or CIS showed high immunolabelling pattern of RANKL, TNF-α, and IL-1β, moderate of BAX, and low of HIF-1α. Histological analysis showed severe tissue breakdown in the groups with EP and treated with 5-FU or CIS.
CONCLUSIONS: Chemotherapy with antineoplastic agents 5-FU and CIS increased the intensity and duration of the inflammation and compromised tissue repair by reduction in cellular and vascular turnover. The more severe periodontal breakdown was caused by 5-FU.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Alveolar bone loss; Antineoplastic agents; Cisplatin; Fluorouracil; Periodontitis

Mesh:

Substances:

Year:  2021        PMID: 34633539     DOI: 10.1007/s00520-021-06586-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  42 in total

Review 1.  Host responses in maintaining periodontal health and determining periodontal disease.

Authors:  Harvey A Schenkein
Journal:  Periodontol 2000       Date:  2006       Impact factor: 7.589

Review 2.  Inflammatory and immune pathways in the pathogenesis of periodontal disease.

Authors:  Ali Cekici; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

3.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Authors:  Jochen H Lorch; Olga Goloubeva; Robert I Haddad; Kevin Cullen; Nicholas Sarlis; Roy Tishler; Ming Tan; John Fasciano; Daniel E Sammartino; Marshall R Posner
Journal:  Lancet Oncol       Date:  2011-01-11       Impact factor: 41.316

4.  Treatment of experimental periodontal disease by photodynamic therapy in immunosuppressed rats.

Authors:  Leandro Araújo Fernandes; Juliano Milanezi de Almeida; Leticia Helena Theodoro; Alvaro Francisco Bosco; Maria José Hitomi Nagata; Thiago Marchi Martins; Tetuo Okamoto; Valdir Gouveia Garcia
Journal:  J Clin Periodontol       Date:  2009-03       Impact factor: 8.728

5.  Simvastatin therapy in cyclosporine A-induced alveolar bone loss in rats.

Authors:  P O Nassar; C A Nassar; M R Guimarães; S G Aquino; D C Andia; M N Muscara; D M P Spolidorio; C Rossa; L C Spolidorio
Journal:  J Periodontal Res       Date:  2008-12-11       Impact factor: 4.419

Review 6.  5-fluorouracil: mechanisms of action and clinical strategies.

Authors:  Daniel B Longley; D Paul Harkin; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

7.  Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model.

Authors:  H J Guchelaar; I Vermes; R P Koopmans; C P Reutelingsperger; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

8.  Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

Authors:  J B Vermorken; F Peyrade; J Krauss; R Mesía; E Remenar; T C Gauler; U Keilholz; J P Delord; P Schafhausen; J Erfán; T H Brümmendorf; L Iglesias; U Bethe; C Hicking; P M Clement
Journal:  Ann Oncol       Date:  2014-03       Impact factor: 32.976

Review 9.  Oral complications and management strategies for patients undergoing cancer therapy.

Authors:  Hai Ming Wong
Journal:  ScientificWorldJournal       Date:  2014-01-08

Review 10.  Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems.

Authors:  José L Arias
Journal:  Molecules       Date:  2008-10-01       Impact factor: 4.411

View more
  1 in total

1.  Integrative Analysis of Deregulated miRNAs Reveals Candidate Molecular Mechanisms Linking H. pylori Infected Peptic Ulcer Disease with Periodontitis.

Authors:  Ning Li; Zhen Wang
Journal:  Dis Markers       Date:  2022-01-29       Impact factor: 3.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.